Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

PMID:
30625070
2.

Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M.

J Thromb Haemost. 2018 Apr;16(4):618-629. doi: 10.1111/jth.13956. Epub 2018 Feb 17.

PMID:
29356300
3.

Targeting anticoagulant protein S to improve hemostasis in hemophilia.

Prince R, Bologna L, Manetti M, Melchiorre D, Rosa I, Dewarrat N, Suardi S, Amini P, Fernández JA, Burnier L, Quarroz C, Reina Caro MD, Matsumura Y, Kremer Hovinga JA, Griffin JH, Simon HU, Ibba-Manneschi L, Saller F, Calzavarini S, Angelillo-Scherrer A.

Blood. 2018 Mar 22;131(12):1360-1371. doi: 10.1182/blood-2017-09-800326. Epub 2018 Jan 9.

4.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.

Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN.

Blood Adv. 2017 Apr 6;1(10):590-600. doi: 10.1182/bloodadvances.2017005124. eCollection 2017 Apr 11.

5.

Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura.

Little DJ, Mathias LM, Page EE, Kremer Hovinga JA, Vesely SK, George JN.

Kidney Int Rep. 2017 Jun 21;2(6):1088-1095. doi: 10.1016/j.ekir.2017.06.007. eCollection 2017 Nov.

6.

Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Scully M, Knöbl P, Kentouche K, Rice L, Windyga J, Schneppenheim R, Kremer Hovinga JA, Kajiwara M, Fujimura Y, Maggiore C, Doralt J, Hibbard C, Martell L, Ewenstein B.

Blood. 2017 Nov 9;130(19):2055-2063. doi: 10.1182/blood-2017-06-788026. Epub 2017 Sep 14.

7.

Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20.

Ayanambakkam A, Kremer Hovinga JA, Vesely SK, George JN.

Am J Hematol. 2017 Nov;92(11):E644-E646. doi: 10.1002/ajh.24885. Epub 2017 Sep 8. No abstract available.

8.

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H, Zeldin RK.

J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.

9.

Thrombotic thrombocytopenic purpura.

Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K.

Nat Rev Dis Primers. 2017 Apr 6;3:17020. doi: 10.1038/nrdp.2017.20. Review.

PMID:
28382967
10.

Progress in Haemostasis. From individual patients to pathophysiological insights.

Kremer Hovinga JA, Scharf RE.

Hamostaseologie. 2017 Jan 31;37(1):9-11. No abstract available.

PMID:
28139815
11.

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.

Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura.

J Thromb Haemost. 2017 Feb;15(2):312-322. doi: 10.1111/jth.13571. Epub 2017 Jan 30.

12.

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.

Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN.

Blood. 2016 Oct 27;128(17):2175-2178. Epub 2016 Sep 13. No abstract available.

13.

Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling.

Kölm R, Schaller M, Roumenina LT, Niemiec I, Kremer Hovinga JA, Khanicheh E, Kaufmann BA, Hopfer H, Trendelenburg M.

J Immunol. 2016 Nov 1;197(9):3669-3679. Epub 2016 Oct 3.

14.

Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review.

Nagler M, Kremer Hovinga JA, Alberio L, Peter-Salonen K, von Tengg-Kobligk H, Lottaz D, Neerman-Arbez M, Lämmle B.

Thromb Haemost. 2016 Sep 27;116(4):722-32. doi: 10.1160/TH16-02-0082. Epub 2016 Jul 7. Review.

PMID:
27384135
15.

Thrombotic thrombocytopenic pupura (TTP) dinner symposium proceedings.

Pavenski K, Cataland S, Kremer Hovinga J, Thomas M, Vanhoorelbeke K.

Expert Rev Hematol. 2016 Aug;9(8):733-5. doi: 10.1080/17474086.2016.1198895. Epub 2016 Jun 22.

PMID:
27269186
16.

Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.

Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN.

Blood. 2016 Jun 16;127(24):3092-4. doi: 10.1182/blood-2016-03-703827. Epub 2016 Apr 8. No abstract available.

17.

Acquired intracoronary ADAMTS13 deficiency and VWF retention at sites of critical coronary stenosis in patients with STEMI.

Pedrazzini G, Biasco L, Sulzer I, Anesini A, Moccetti T, Kremer Hovinga JA, Alberio L.

Blood. 2016 Jun 9;127(23):2934-6. doi: 10.1182/blood-2015-12-688010. Epub 2016 Mar 31. No abstract available.

18.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators.

N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533.

19.

Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency.

Fan X, Kremer Hovinga JA, Shirotani-Ikejima H, Eura Y, Hirai H, Honda S, Kokame K, Taleghani MM, von Krogh AS, Yoshida Y, Fujimura Y, Lämmle B, Miyata T.

Int J Hematol. 2016 Mar;103(3):283-91. doi: 10.1007/s12185-015-1933-7. Epub 2016 Feb 1.

20.

High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence.

von Krogh AS, Quist-Paulsen P, Waage A, Langseth ØO, Thorstensen K, Brudevold R, Tjønnfjord GE, Largiadèr CR, Lämmle B, Kremer Hovinga JA.

J Thromb Haemost. 2016 Jan;14(1):73-82. doi: 10.1111/jth.13186. Epub 2016 Jan 8.

21.

ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study.

von Krogh AS, Kremer Hovinga JA, Romundstad PR, Roten LT, Lämmle B, Waage A, Quist-Paulsen P.

Thromb Res. 2015 Aug;136(2):282-8. doi: 10.1016/j.thromres.2015.06.022. Epub 2015 Jun 18.

PMID:
26139087
22.

Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy.

von Auer C, von Krogh AS, Kremer Hovinga JA, Lämmle B.

Thromb Res. 2015 Feb;135 Suppl 1:S30-3. doi: 10.1016/S0049-3848(15)50437-4. Epub 2015 Feb 9. Review.

PMID:
25903530
23.

Successful liver transplantation in a child with acute-on-chronic liver failure and acquired thrombotic thrombocytopenic purpura.

Arni D, Gumy-Pause F, Ansari M, Kremer Hovinga JA, McLin VA.

Liver Transpl. 2015 May;21(5):704-6. doi: 10.1002/lt.24096. Epub 2015 Apr 1. No abstract available.

24.

Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH.

Hubbard AR, Heath AB, Kremer Hovinga JA; Subcommittee on von Willebrand Factor.

J Thromb Haemost. 2015 Jun;13(6):1151-3. No abstract available.

25.

Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura.

Edgar CE, Terrell DR, Vesely SK, Wren JD, Dozmorov IM, Niewold TB, Brown M, Zhou F, Frank MB, Merrill JT, Kremer Hovinga JA, Lämmle B, James JA, George JN, Farris AD.

PLoS One. 2015 Feb 11;10(2):e0117614. doi: 10.1371/journal.pone.0117614. eCollection 2015.

26.

[Thrombotic thrombocytopenic purpura--an often missed diagnosis].

Adler M, Kremer Hovinga JA, Lämmle B.

Rev Med Suisse. 2014 Nov 26;10(452):2280-4. Review. French.

PMID:
25562980
27.

Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies.

Jiménez-Alcázar M, Napirei M, Panda R, Köhler EC, Kremer Hovinga JA, Mannherz HG, Peine S, Renné T, Lämmle B, Fuchs TA.

J Thromb Haemost. 2015 May;13(5):732-42. doi: 10.1111/jth.12796. Epub 2015 Apr 13.

28.

The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs.

Schaller M, Vogel M, Kentouche K, Lämmle B, Kremer Hovinga JA.

Blood. 2014 Nov 27;124(23):3469-79. doi: 10.1182/blood-2014-04-561142. Epub 2014 Sep 26.

29.

Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura.

Raval JS, Padmanabhan A, Kremer Hovinga JA, Kiss JE.

Am J Hematol. 2015 Jan;90(1):E22. doi: 10.1002/ajh.23851. Epub 2014 Oct 18. No abstract available.

30.

Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura.

Falter T, Kremer Hovinga JA, Lackner K, Füllemann HG, Lämmle B, Scharrer I.

Hamostaseologie. 2014;34(3):244-8. doi: 10.5482/HAMO-14-03-0023. Epub 2014 Jul 4.

PMID:
24994604
31.

The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications.

von Krogh AS, Kremer Hovinga JA, Tjønnfjord GE, Ringen IM, Lämmle B, Waage A, Quist-Paulsen P.

Thromb Haemost. 2014 Jun;111(6):1180-3. doi: 10.1160/TH13-08-0713. Epub 2014 Feb 6. No abstract available.

PMID:
24499950
32.

Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.

Jiang Y, McIntosh JJ, Reese JA, Deford CC, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, Knudtson EJ, George JN.

Blood. 2014 Mar 13;123(11):1674-80. doi: 10.1182/blood-2013-11-538900. Epub 2014 Jan 7.

33.

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.

Ferrari S, Palavra K, Gruber B, Kremer Hovinga JA, Knöbl P, Caron C, Cromwell C, Aledort L, Plaimauer B, Turecek PL, Rottensteiner H, Scheiflinger F.

Haematologica. 2014 Apr;99(4):779-87. doi: 10.3324/haematol.2013.094151. Epub 2013 Nov 15.

34.

Plasma DNA is Elevated in Patients with Deep Vein Thrombosis.

Diaz JA, Fuchs TA, Jackson TO, Kremer Hovinga JA, Lämmle B, Henke PK, Myers DD Jr, Wagner DD, Wakefield TW; for the Michigan Research Venous Group*.

J Vasc Surg Venous Lymphat Disord. 2013 Oct 1;1(4). doi: 10.1016/j.jvsv.2012.12.002.

35.

Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene.

Rank CU, Kremer Hovinga J, Taleghani MM, Lämmle B, Gøtze JP, Nielsen OJ.

Eur J Haematol. 2014 Feb;92(2):168-71. doi: 10.1111/ejh.12197. Epub 2013 Dec 10.

PMID:
24033710
36.

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Deford CC, Reese JA, Schwartz LH, Perdue JJ, Kremer Hovinga JA, Lämmle B, Terrell DR, Vesely SK, George JN.

Blood. 2013 Sep 19;122(12):2023-9; quiz 2142. doi: 10.1182/blood-2013-04-496752. Epub 2013 Jul 9.

37.

Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.

Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN.

Pediatr Blood Cancer. 2013 Oct;60(10):1676-82. doi: 10.1002/pbc.24612. Epub 2013 Jun 1.

PMID:
23729372
38.

Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry.

Mansouri Taleghani M, von Krogh AS, Fujimura Y, George JN, Hrachovinová I, Knöbl PN, Quist-Paulsen P, Schneppenheim R, Lämmle B, Kremer Hovinga JA.

Hamostaseologie. 2013 May 29;33(2):138-43. doi: 10.5482/HAMO-13-04-0026. Review.

PMID:
23715103
39.

Thrombotic microangiopathies.

Kremer Hovinga JA.

Hamostaseologie. 2013 May 29;33(2):81. No abstract available.

PMID:
23715101
40.

Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes?

Hausammann S, Vogel M, Kremer Hovinga JA, Lacroix-Desmazes S, Stadler BM, Horn MP.

PLoS One. 2013 Apr 23;8(4):e60688. doi: 10.1371/journal.pone.0060688. Print 2013.

41.

Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response.

Schaller M, Studt JD, Voorberg J, Kremer Hovinga JA.

Hamostaseologie. 2013 May 29;33(2):121-30. doi: 10.5482/HAMO-12-12-0023. Epub 2013 Feb 27. Review.

PMID:
23443151
42.

Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.

Kremer Hovinga JA, Lämmle B.

Hematology Am Soc Hematol Educ Program. 2012;2012:610-6. doi: 10.1182/asheducation-2012.1.610. Review.

PMID:
23233642
43.

Novel ADAMTS13 mutations in an obstetric patient with Upshaw-Schulman syndrome.

Deal T, Kremer Hovinga JA, Marques MB, Adamski J.

J Clin Apher. 2013 Aug;28(4):311-6. doi: 10.1002/jca.21251. Epub 2012 Dec 3.

PMID:
23208954
44.

Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura.

Du VX, van Os G, Kremer Hovinga JA, Dienava-Verdoold I, Wollersheim J, Ruggeri ZM, Fijnheer R, de Groot PG, de Laat B.

Br J Haematol. 2012 Oct;159(1):94-103. doi: 10.1111/bjh.12004. Epub 2012 Aug 9.

PMID:
22881339
45.

Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies.

Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B.

Blood. 2012 Aug 9;120(6):1157-64. doi: 10.1182/blood-2012-02-412197. Epub 2012 May 18.

46.

Improving on nature: redesigning ADAMTS13.

Kremer Hovinga JA, Voorberg J.

Blood. 2012 Apr 19;119(16):3654-5. doi: 10.1182/blood-2012-02-410431. No abstract available.

47.

Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011.

Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, George JN, Vesely SK.

Transfusion. 2012 Dec;52(12):2525-32; quiz 2524. doi: 10.1111/j.1537-2995.2012.03646.x. Epub 2012 Apr 15.

48.

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.

Cataland SR, Peyvandi F, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P.

Am J Hematol. 2012 Apr;87(4):430-2. doi: 10.1002/ajh.23106. Epub 2012 Feb 24. No abstract available.

49.

Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer.

George JN, Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B.

Presse Med. 2012 Mar;41(3 Pt 2):e177-88. doi: 10.1016/j.lpm.2011.10.026. Epub 2012 Jan 13. Review.

PMID:
22244728
50.

Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura.

Froehlich-Zahnd R, George JN, Vesely SK, Terrell DR, Aboulfatova K, Dong JF, Luken BM, Voorberg J, Budde U, Sulzer I, Lämmle B, Kremer Hovinga JA.

Haematologica. 2012 Feb;97(2):297-303. doi: 10.3324/haematol.2011.051433. Epub 2011 Oct 11.

Supplemental Content

Loading ...
Support Center